SNM: Symposium sheds light on molecular neuroimaging

SNM's Molecular Imaging Center of Excellence (MICoE) wrapped up its Molecular Neuroimaging Symposium on May 7 in Bethesda, Md., at the National Institutes of Health (NIH) facility.

The first day of the symposium served as an introduction and general overview of current and new techniques used to study the brain and the focus shifted to translational research on the second day.

Three topics were at the forefront of discussion: brain tumor imaging, neurodegenerative diseases and neuropsychiatric disorders, according to the society.

"Our aim for this meeting is to bring the clinical and research communities together," said Henry F. VanBrocklin, PhD, MICoE president and professor of radiology and director of radiopharmaceutical research in the Center for Functional and Molecular Imaging at the University of California, San Francisco.

"Translating basic research into clinical techniques is a long and arduous task that requires input from both sides and constant communication between the people designing the scanners and probes and those who will eventually use them to improve the clinical care of patients," VanBrocklin added.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.